- Home
- IMMX vs SST Comparison
IMMX vs SST Comparison
Compare IMMX & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- SST
- Stock Information
- Founded
- IMMX 2014
- SST 2013
- Country
- IMMX United States
- SST United States
- Employees
- IMMX N/A
- SST N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- SST Diversified Commercial Services
- Sector
- IMMX Health Care
- SST Consumer Discretionary
- Exchange
- IMMX Nasdaq
- SST Nasdaq
- Market Cap
- IMMX 82.6M
- SST 67.7M
- IPO Year
- IMMX 2021
- SST N/A
- Fundamental
- Price
- IMMX $3.28
- SST $4.37
- Analyst Decision
- IMMX Strong Buy
- SST Strong Buy
- Analyst Count
- IMMX 1
- SST 1
- Target Price
- IMMX $8.00
- SST $10.00
- AVG Volume (30 Days)
- IMMX 769.8K
- SST 25.8K
- Earning Date
- IMMX 11-07-2025
- SST 11-05-2025
- Dividend Yield
- IMMX N/A
- SST N/A
- EPS Growth
- IMMX N/A
- SST N/A
- EPS
- IMMX N/A
- SST N/A
- Revenue
- IMMX N/A
- SST $289,784,000.00
- Revenue This Year
- IMMX N/A
- SST N/A
- Revenue Next Year
- IMMX N/A
- SST $12.20
- P/E Ratio
- IMMX N/A
- SST N/A
- Revenue Growth
- IMMX N/A
- SST N/A
- 52 Week Low
- IMMX $1.34
- SST $2.90
- 52 Week High
- IMMX $4.05
- SST $15.00
- Technical
- Relative Strength Index (RSI)
- IMMX 55.27
- SST 27.38
- Support Level
- IMMX $2.85
- SST $4.35
- Resistance Level
- IMMX $3.53
- SST $4.95
- Average True Range (ATR)
- IMMX 0.38
- SST 0.44
- MACD
- IMMX -0.07
- SST -0.14
- Stochastic Oscillator
- IMMX 34.80
- SST 1.29
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.